Drug profile · INN
dexamethasone sodium phosphate
DEXAMETHASONE SODIUM PHOSPHATE
dexamethasone sodium phosphate (DEXAMETHASONE SODIUM PHOSPHATE) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic, otic. Current US regulatory status: approved.
Drug details — dexamethasone sodium phosphate
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC, OTIC
- Patents
- 20
- Programs
- 169
- Data quality
- 0.89
Quick answer
dexamethasone sodium phosphate (DEXAMETHASONE SODIUM PHOSPHATE) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic, otic. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
GSK’s Blenrep returns to the US market after FDA approves resubmission
The FDA has approved GSK’s Blenrep in combination with bortezomib and dexamethasone, clearing the drug’s return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.
GSK Blenrep wins FDA approval in relapsed multiple myeloma
GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.
Pipeline programs
Related & competitor drugs
Related patents
-
US 12331126
OX40-binding polypeptides and uses thereof
granted -
US 12311059
Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
granted -
US 12285435
Multivesicular liposome formulations of dexamethasone
granted -
US 12084502
CD33-binding polypeptides and uses thereof
granted -
US 12043667
CLEC12a binding polypeptides and uses thereof
granted -
US 12012459
OX40-binding polypeptides and uses thereof
granted -
US 11965017
Serpin fusion polypeptides and methods of use thereof
granted -
US 11919963
CD123-binding polypeptides and uses thereof
granted -
US 11866507
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
granted -
US 11827691
Serpin fusion polypeptides and methods of use thereof
granted -
US 11566078
PDL1-binding proteins
granted -
US 11560428
CD33-binding polypeptides and uses thereof
granted -
US 11434297
CD123-binding polypeptides and uses thereof
granted -
US 11046752
Serpin fusion polypeptides and methods of use thereof
granted -
US 10745466
Type III secretion system targeting molecules
granted -
US 10730929
Serpin fusion polypeptides and methods of use thereof
granted -
US 10723785
Serpin fusion polypeptides and methods of use thereof
granted -
US 10400029
Serpin fusion polypeptides and methods of use thereof
granted -
US 10344078
Type III secretion system targeting molecules
granted -
US 10093742
Multispecific GITR-binding fusion proteins and methods of use thereof
granted
Frequently asked questions
What is dexamethasone sodium phosphate?
dexamethasone sodium phosphate (DEXAMETHASONE SODIUM PHOSPHATE) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic, otic. Current US regulatory status: approved.
What is the brand name for dexamethasone sodium phosphate?
DEXAMETHASONE SODIUM PHOSPHATE is a marketed brand name for dexamethasone sodium phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dexamethasone sodium phosphate?
dexamethasone sodium phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.